T2D2
MCID: TYP049
MIFTS: 21

Type 2 Diabetes Mellitus 2 (T2D2)

Categories: Endocrine diseases, Genetic diseases, Immune diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Type 2 Diabetes Mellitus 2

MalaCards integrated aliases for Type 2 Diabetes Mellitus 2:

Name: Type 2 Diabetes Mellitus 2 57
Diabetes Mellitus, Noninsulin-Dependent, 2 57 29 13 70
Diabetes Mellitus, Noninsulin-Dependent, 2; Niddm2 57
Noninsulin-Dependent Diabetes Mellitus 2 57
Niddm2 57
T2d2 57

Classifications:



External Ids:

OMIM® 57 601407
MedGen 41 C1832387
UMLS 70 C1832387

Summaries for Type 2 Diabetes Mellitus 2

MalaCards based summary : Type 2 Diabetes Mellitus 2, also known as diabetes mellitus, noninsulin-dependent, 2, is related to type 2 diabetes mellitus and diabetes mellitus. An important gene associated with Type 2 Diabetes Mellitus 2 is NIDDM2 (Non Insulin Dependent Diabetes Mellitus 2). Affiliated tissues include ovary, endothelial and pancreatic islet.

More information from OMIM: 601407

Symptoms & Phenotypes for Type 2 Diabetes Mellitus 2

Clinical features from OMIM®:

601407 (Updated 05-Apr-2021)

Drugs & Therapeutics for Type 2 Diabetes Mellitus 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Examining the Role of Continuous Glucose Monitoring (CGM) in Non-Insulin Treated Type 2 Diabetes Completed NCT01614262
2 Effect of Glucose Monitoring on Patient and Provider Outcomes in Non-insulin Treated Diabetes Completed NCT02033499

Search NIH Clinical Center for Type 2 Diabetes Mellitus 2

Genetic Tests for Type 2 Diabetes Mellitus 2

Genetic tests related to Type 2 Diabetes Mellitus 2:

# Genetic test Affiliating Genes
1 Diabetes Mellitus, Noninsulin-Dependent, 2 29

Anatomical Context for Type 2 Diabetes Mellitus 2

MalaCards organs/tissues related to Type 2 Diabetes Mellitus 2:

40
Ovary, Endothelial, Pancreatic Islet

Publications for Type 2 Diabetes Mellitus 2

Articles related to Type 2 Diabetes Mellitus 2:

(show all 48)
# Title Authors PMID Year
1
Association of single-nucleotide polymorphisms in the suppressor of cytokine signaling 2 (SOCS2) gene with type 2 diabetes in the Japanese. 57
16406727 2006
2
Genomewide search for type 2 diabetes mellitus susceptibility loci in Finnish families: the Botnia study. 57
11791216 2002
3
Evidence of a novel type 2 diabetes locus 50 cM centromeric to NIDDM2 on chromosome 12q. 57
10535461 1999
4
Novel susceptibility gene for late-onset NIDDM is localized to human chromosome 12q. 57
9792550 1998
5
Characterization of the MODY3 phenotype. Early-onset diabetes caused by an insulin secretion defect. 57
9045858 1997
6
Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families. 57
8782826 1996
7
Perfluorinated polymer modified vertical silicon nanowires as ultra low noise laser desorption ionization substrate for salivary metabolites profiling. 61
33592752 2021
8
Clinical performance of titanium-zirconium implants with a hydrophilic surface in patients with controlled type 2 diabetes mellitus: 2-year results from a prospective case-control clinical study. 61
31701247 2020
9
Prevalence of Type 2 Diabetes Mellitus among People Attending Medical Camp in a Community Hospital. 61
32538925 2020
10
Three-Dimensional Echocardiography in Evaluating LA Volumes and Functions in Diabetic Normotensive Patients without Symptomatic Cardiovascular Disease. 61
32922998 2020
11
Coronavirus infection in patients with diabetes. 61
32523141 2020
12
Diabetes Mellitus Type Has Impact on Cutaneous Silent Period. 61
31819306 2019
13
Type of Diabetes Mellitus Has Influence on Electrophysiological Parameters. 61
31452568 2019
14
The association between GAD65 antibody levels and incident Type 2 Diabetes Mellitus in an adult population: A meta-analysis. 61
30853448 2019
15
Prevalence and characteristics of apparent treatment-resistant hypertension in older people in China: a cross-sectional study. 61
30512984 2019
16
IMPROVEMENT OF TREATMENT IN PERSONS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS. 61
30618388 2018
17
miR‑6835‑3p regulates the function of pancreatic islet cells by modulating the expression of AdipoR1. 61
29916530 2018
18
"You've Got to Love Yourself": Photovoice Stories From African Americans and Hispanic/Latinos Living With Diabetes. 61
28826295 2018
19
Influence of implant location in patients with and without type 2 diabetes mellitus: 2-year follow-up. 61
28499506 2017
20
A new method to evaluate the dose-effect relationship of a TCM formula Gegen Qinlian Decoction: "Focus" mode of integrated biomarkers. 61
28317873 2017
21
Impact of different dietary approaches on glycemic control and cardiovascular risk factors in patients with type 2 diabetes: a protocol for a systematic review and network meta-analysis. 61
28320464 2017
22
Protocol for Evaluating the Cardio-Ankle Vascular Index to Predict Cardiovascular Events in Japan: A Prospective Multicenter Cohort Study. 61
28275590 2017
23
Intermittent Vagal Nerve Block for Improvements in Obesity, Cardiovascular Risk Factors, and Glycemic Control in Patients with Type 2 Diabetes Mellitus: 2-Year Results of the VBLOC DM2 Study. 61
26471783 2016
24
Erratum to: Intermittent Vagal Nerve Block for Improvements in Obesity, Cardiovascular Risk Factors, and Glycemic Control in Patients with Type 2 Diabetes Mellitus: 2-Year Results of the VBLOC DM2 Study. 61
26525980 2016
25
Management of patients with type 2 diabetes and multiple chronic conditions: A Delphi consensus of the Spanish Society of Internal Medicine. 61
26586286 2016
26
Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes. 61
27669970 2016
27
Clinical course of diabetes after gastrectomy according to type of reconstruction in patients with concurrent gastric cancer and type 2 diabetes. 61
25190521 2015
28
Small molecules as potent protein tyrosine phosphatase 1B (PTP1B) inhibitors documented in patents from 2009 to 2013. 61
25643610 2015
29
Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans. 61
24074237 2014
30
Restoration of glycemic control in patients with type 2 diabetes mellitus after bariatric surgery is associated with reduction in microparticles. 61
22093380 2013
31
Exercise capacity and progression from prehypertension to hypertension. 61
22753224 2012
32
[Therapeutic compliance in patients with arterial hypertension and type 2 diabetes mellitus]. 61
22138203 2012
33
The use of oral budesonide in adolescents and adults with protein-losing enteropathy after the Fontan operation. 61
21784410 2011
34
Maternal serum adiponectin multimers in gestational diabetes. 61
19530957 2009
35
Safety of prescribing PDE-5 inhibitors via e-medicine vs traditional medicine. 61
18674473 2008
36
Glucometabolic state of in-hospital patients with primary hypertension in sub-population of partial regions in China. 61
18200032 2008
37
Salivary histamine level as a predictor of periodontal disease in type 2 diabetic and non-diabetic subjects. 61
16945035 2006
38
Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus. 61
16682971 2006
39
Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. 61
15270785 2004
40
Cardiovascular risk factors in the Lublin Region population with and without type-2 diabetes mellitus. 61
15323239 2003
41
Role of chromium supplementation in Indians with type 2 diabetes mellitus. 61
12550067 2002
42
[Gastric emptying disorders in diabetes mellitus]. 61
12600185 2002
43
Analysis of the insulin-sensitive phosphodiesterase 3B gene in type 2 diabetes. 61
11640991 2001
44
Effect of enalapril on diabetic nephropathy in OLETF rats: the role of an anti-oxidative action in its protective properties. 61
11553023 2001
45
[Insulinemia--a marker of early diagnosis and control of efficacy of treatment of type II diabetes]. 61
11928588 2001
46
Interaction of hypertension and diabetes on impairment of endothelial function. 61
11780427 2001
47
Improving management of type 2 diabetes mellitus: 2. Biguanides. 61
10887428 1999
48
Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects. 61
9831697 1998

Variations for Type 2 Diabetes Mellitus 2

Expression for Type 2 Diabetes Mellitus 2

Search GEO for disease gene expression data for Type 2 Diabetes Mellitus 2.

Pathways for Type 2 Diabetes Mellitus 2

GO Terms for Type 2 Diabetes Mellitus 2

Sources for Type 2 Diabetes Mellitus 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....